Significantly, the ICC subgroup with Beclin 1 low expression had a worsened 3-year OS rate than ECC subset (low Beclin 1 ICC VS low Beclin ECC: 16.5% VS 29.5%, P = 0.010, Figure 4A), especially than the Beclin 1 highly expressed ECC patients (low Beclin 1 ICC VS high Beclin ECC: 16.5% VS 36.9%, P = 0.012, Figure 4C). Here, BECN1 is linked to intrahepatic cholangiocarcinoma.